[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
February 2018

Noninvasive Gene Expression Testing in Amelanotic Melanoma

Author Affiliations
  • 1Childs Dermatology, College Station, Texas
JAMA Dermatol. 2018;154(2):223-224. doi:10.1001/jamadermatol.2017.4773

Not missing melanomas in daily practice keeps dermatologists up at night and is a challenge even for dermatologists who see pigmented lesion cases regularly. Ferris et al1 describe the utility of a noninvasive gene expression test capable of differentiating primary melanomas from nonmelanoma pigmented skin lesions. However, neither the article by Ferris et al1 nor the underlying validation study by Gerami et al2 describe scenarios where the LINC00518 and PRAME melanoma gene expression test, termed pigmented lesion assay by the authors, is used in even more difficult cases to diagnose amelanotic melanomas.

×